According to FutureWise analysis the market for brain tumor drug in 2023 is US$ 3.04 billion, and is expected to reach US$ 5.94 billion by 2031 at a CAGR of 8.7%.
Brain cancer occurs when cells in the brain grow out of control and form tumors. The condition involves the development of cancer cells in the brain. It is believed that cancer cells proliferate to form tumors, which disrupt the functioning of the brain, such as sensation, muscle control, memory, and other bodily functions. Cancer cells emerge from brain tissue in primary brain tumors, whereas cancer cells spread from other parts of the body to the brain in metastatic or secondary brain tumors. Symptoms, general health, and treatment preferences will all determine the treatment of a brain tumor, as well as the size, type, and location of the tumor. Clinical teams often collaborate to develop a patient's overall treatment plan, which may include a variety of treatments, for brain tumors. A multidisciplinary team is what this is called. Your care team may include physician assistants, oncology nurses, nurse practitioners, pharmacists, counselors, nutritionists, social workers, rehabilitation specialists, and others. Having a care team that specializes in treating brain tumors is crucial, which may involve consulting with medical professionals outside your immediate area to assist with diagnosis and treatment.
If the entire tumor can be removed, surgery might be the only option for a low-grade brain tumor. If the tumor remains visible after surgery, radiation therapy and chemotherapy may be used. In the treatment of higher-grade cancers, surgery is often followed by radiation therapy and chemotherapy. Temozolomide, carmustine, cisplatin, bevacizumab, geftinib, and erlotinib are the main types of drugs used to treat brain tumors. Temozolomide is intended to treat some types of brain cancer (e.g., glioblastoma multiforme, anaplastic astrocytoma) in individuals who have had tumors return or have recently been diagnosed with tumors. As antineoplastics (cancer medicines), it belongs to a group of drugs called antineoplastics. Medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal tumors (PNET), and others (glioma, acoustic neuroma, meningioma) are among the types of tumors. In the global market for brain tumors, the increasing prevalence of neurological disorders is the major driving force. Due to longer life expectancy, increased exposure to infections, and sedentary lifestyles, neurological disorders are identified as one of the most prevalent disorders. It is expected that the growing popularity of targeted therapies will affect the sales of conventional chemical brain tumor drugs, thereby restraining the market's growth.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Brain Tumor Drug Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Brain Tumor Drug Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.